Tibet Weixinkang Medicine Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 37.55%

Tibet Weixinkang Medicine Co Ltd (603676) has an Asset Resilience Ratio of 37.55% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Tibet Weixinkang Medicine Co Ltd for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥717.00 Million
≈ $104.92 Million USD Cash + Short-term Investments

Total Assets

CN¥1.91 Billion
≈ $279.41 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Tibet Weixinkang Medicine Co Ltd's Asset Resilience Ratio has changed over time. See Tibet Weixinkang Medicine Co Ltd (603676) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Tibet Weixinkang Medicine Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Tibet Weixinkang Medicine Co Ltd stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥717.00 Million 37.55%
Total Liquid Assets CN¥717.00 Million 37.55%

Asset Resilience Insights

  • Very High Liquidity: Tibet Weixinkang Medicine Co Ltd maintains exceptional liquid asset reserves at 37.55% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Tibet Weixinkang Medicine Co Ltd Industry Peers by Asset Resilience Ratio

Compare Tibet Weixinkang Medicine Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
Drug Manufacturers - Specialty & Generic 0.44%
Emcure Pharmaceuticals Ltd
NSE:EMCURE
Drug Manufacturers - Specialty & Generic 1.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Ningbo Menovo Pharm Co Ltd
SHG:603538
Drug Manufacturers - Specialty & Generic 2.69%
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
Drug Manufacturers - Specialty & Generic 20.24%
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
Drug Manufacturers - Specialty & Generic 0.40%

Annual Asset Resilience Ratio for Tibet Weixinkang Medicine Co Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Tibet Weixinkang Medicine Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 43.32% CN¥803.00 Million
≈ $117.50 Million
CN¥1.85 Billion
≈ $271.25 Million
+8.13pp
2023-12-31 35.19% CN¥625.32 Million
≈ $91.50 Million
CN¥1.78 Billion
≈ $260.02 Million
+17.95pp
2022-12-31 17.24% CN¥287.00 Million
≈ $42.00 Million
CN¥1.66 Billion
≈ $243.60 Million
-14.04pp
2021-12-31 31.28% CN¥467.77 Million
≈ $68.45 Million
CN¥1.50 Billion
≈ $218.85 Million
+5.10pp
2020-12-31 26.18% CN¥356.00 Million
≈ $52.09 Million
CN¥1.36 Billion
≈ $199.02 Million
-2.18pp
2019-12-31 28.35% CN¥369.90 Million
≈ $54.13 Million
CN¥1.30 Billion
≈ $190.91 Million
-9.68pp
2017-12-31 38.04% CN¥386.71 Million
≈ $56.59 Million
CN¥1.02 Billion
≈ $148.76 Million
+23.83pp
2016-12-31 14.21% CN¥78.50 Million
≈ $11.49 Million
CN¥552.36 Million
≈ $80.83 Million
--
pp = percentage points

About Tibet Weixinkang Medicine Co Ltd

SHG:603676 China Drug Manufacturers - Specialty & Generic
Market Cap
$677.53 Million
CN¥4.63 Billion CNY
Market Cap Rank
#11063 Global
#3282 in China
Share Price
CN¥10.64
Change (1 day)
+0.38%
52-Week Range
CN¥9.72 - CN¥14.17
All Time High
CN¥24.05
About

Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. The company offers parenteral nutrition vitamins; electrolyte supplements; intravenous iron, trace, electrolytes, and amino acids supplements; antibiotics; acetylcysteine solution for inhalation; medicine for liver diseases; and other special fields. I… Read more